These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19095447)

  • 1. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
    Bellenie BR; Barton NP; Emmons AJ; Heer JP; Salvagno C
    Bioorg Med Chem Lett; 2009 Feb; 19(3):990-4. PubMed ID: 19095447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY; Wo NC; Cheng LL; Manning M
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
    J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
    J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxytocin receptor antagonists. Update.
    Goodwin TM; Zograbyan A
    Clin Perinatol; 1998 Dec; 25(4):859-71, vi. PubMed ID: 9891619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.
    Akerlund M
    Rocz Akad Med Bialymst; 2004; 49():18-21. PubMed ID: 15631309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.
    Manning M; Cheng LL; Klis WA; Stoev S; Przybylski J; Bankowski K; Sawyer WH; Barberis C; Chan WY
    Adv Exp Med Biol; 1995; 395():559-83. PubMed ID: 8714021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin-modeling of an activated state.
    Slusarz MJ; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):171-9. PubMed ID: 16114099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
    J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
    Chini B; Manning M; Guillon G
    Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
    Pierzynski P
    Reprod Biomed Online; 2011 Jan; 22(1):9-16. PubMed ID: 21130036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tocolysis. Atosiban, an ocytcin-receptor antagonist].
    Schmitz T; Cabrol D
    J Gynecol Obstet Biol Reprod (Paris); 2001 May; 30(3):238-45. PubMed ID: 11397999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and design of novel vasopressin hypotensive peptide agonists.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Recept Signal Transduct Res; 1999; 19(1-4):631-44. PubMed ID: 10071789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
    Borthwick AD; Liddle J
    Med Res Rev; 2011 Jul; 31(4):576-604. PubMed ID: 20027670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication.
    Laudanski T; Pierzynski P
    Gynecol Endocrinol; 2003 Jun; 17(3):261-7. PubMed ID: 12857435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.